Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 4/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417118 | 0.88 | S1PR3 (0.54) | S1PR3S1PR1TRPA1 | |
| SCHEMBL3821201 | 0.83 | S1PR3 (0.47) | S1PR3S1PR1LRRK2S1PR4GRM4 | |
| SCHEMBL6416168 | 0.80 | CHRNA1 (0.57) | ANO1POLBAPEX1MAPT | |
| SCHEMBL22099996 | 0.80 | S1PR3 (0.54) | S1PR3S1PR1LRRK2S1PR4 | |
| SCHEMBL3612508 | 0.80 | VNN1 (0.47) | S1PR3S1PR1S1PR4GRM4POLB | |
| SCHEMBL13701824 | 0.79 | LRRK2 (0.54) | S1PR3ANO1LRRK2POLBVNN1 | |
| SCHEMBL13702420 | 0.79 | VNN1 (0.44) | S1PR3S1PR1LRRK2S1PR4GRM4 | |
| SCHEMBL22099891 | 0.79 | S1PR3 (0.56) | S1PR3S1PR1LRRK2S1PR4POLB | |
| SCHEMBL3616560 | 0.78 | TRPA1 (0.51) | S1PR3S1PR1S1PR4GRM4VNN1 | |
| SCHEMBL18013247 | 0.78 | ACLY (0.46) | S1PR3S1PR1S1PR4GRM4VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | S1PR3 509/4885S1PR1 750/4885ANO1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.